MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-12-2024
Cutera Cost of Revenue 2011-2025 | CUTR
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Cutera
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 171 M | 113 M | 98.2 M | 71.9 M | 83.5 M | 82.3 M | 65.4 M | 49.9 M | 40.5 M | 34.8 M | 32.7 M | 35.7 M | 26 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 171 M | 26 M | 69.6 M |
Quarterly Cost of Revenue Cutera
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.7 M | 26.7 M | - | 40 M | 35.7 M | 30.1 M | - | 28.6 M | 29.2 M | 26.2 M | - | 24 M | 24.8 M | 22 M | 21.9 M | 17.4 M | 14.7 M | 17.9 M | 23 M | 19.9 M | 21.9 M | 18.7 M | 26.7 M | 18.7 M | 20.2 M | 16.8 M | 20.3 M | 16 M | 15.3 M | 13.8 M | 16 M | 12.5 M | 11.5 M | 9.95 M | 12.1 M | 9.59 M | 9.69 M | 9.05 M | 11.7 M | 7.94 M | 7.85 M | 7.3 M | 9.2 M | 7.65 M | 8.44 M | 7.42 M | 9.79 M | 8.83 M | 9.27 M | 7.84 M | 7.51 M | 6.77 M | 6.48 M | 5.22 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 40 M | 5.22 M | 16.5 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.86 | -3.26 % | $ 134 M |  USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Abiomed
ABMD
|
162 M | - | - | $ 17.2 B | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 307.92 | -1.93 % | $ 8.69 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 45.13 | -2.67 % | $ 6.72 K | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Abbott Laboratories
ABT
|
18.7 B | $ 125.1 | 1.48 % | $ 218 B | USA |
 |
Boston Scientific Corporation
BSX
|
5.26 B | $ 92.34 | 0.64 % | $ 136 B | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 2.56 | 8.94 % | $ 95.5 M |  France |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 0.92 | -4.72 % | $ 14.8 M | USA |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 96.35 | -1.06 % | $ 1.22 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
56.1 M | $ 17.7 | -3.46 % | $ 408 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
383 M | $ 62.79 | -1.82 % | $ 3.41 B |  Britain |
 |
Pulmonx Corporation
LUNG
|
21.8 M | $ 2.53 | 0.86 % | $ 99 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
InMode Ltd.
INMD
|
77.8 M | $ 14.56 | 0.76 % | $ 1.15 B |  Israel |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 9.88 | 0.05 % | $ 709 M | Israel |
 |
Myomo
MYO
|
5.3 M | $ 1.06 | -1.85 % | $ 7.47 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 13.41 | -4.56 % | $ 1.03 B | USA |
 |
NuVasive
NUVA
|
337 M | - | - | $ 2.07 B | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 165.15 | 0.78 % | $ 12.4 B | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 1.07 | -3.18 % | $ 110 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 12.81 | -1.23 % | $ 346 M | USA |
 |
Orthofix Medical
OFIX
|
254 M | $ 15.51 | -1.27 % | $ 591 M |  Curacao |
 |
AxoGen
AXGN
|
45.4 M | $ 30.33 | 1.15 % | $ 1.34 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
574 M | $ 40.78 | 2.33 % | $ 1.26 B | USA |
|
LENSAR
LNSR
|
27.6 M | $ 11.48 | -0.17 % | $ 132 M | USA |